CI

At a glance

ClinicalIndex Comparison Record
Phase 2Active· 46 enrolled
Drug / intervention
Bortezomib +2 moredrug
Likely dose
Bortezomib 1.6 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00492050
NCT00492050Phase 2Active
CompareCT.gov

Primary Treatment of Waldenstrom's Macroglobulinemia With Bortezomib (Velcade) and Rituximab (Rituxan) Followed by Autologous Stem Cell Collection

M.D. Anderson Cancer Center·interventional·Posted Jun 27, 2007·Updated Mar 11, 2026

In Brief

A Phase 2 clinical trial evaluating Bortezomib, Rituximab, and 1 other intervention for Waldenstrom's Macroglobulinemia. Active but no longer recruiting, targeting 46 participants across 1 site.

Detailed Summary

The main goal of this clinical research study is to learn if Velcade ® (bortezomib) given with rituximab can help to control WM. This drug combination will allow researchers to collect your stem cells in case it is possible to transplant the stem cells as treatment if your WM gets worse. Researchers will also look at the safety and tolerability of this drug combination followed by treatment with other drug combinations.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsWaldenstrom's Macroglobulinemia
CountriesUnited States
CollaboratorsMillennium Pharmaceuticals, Inc.

Timeline

Phase 2ActiveOverdue
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJun 27, 2007
Enrollment StartAug 2, 2006
Primary CompletionFeb 28, 2021
Study CompletionJun 28, 2026
TodayJul 2, 2026
Enrollment to primary: 14.6 yearsPosted 19.0 years ago

Interventions

Bortezomibdrug

1.6 mg/m\^2 IV Weekly on Days 1, 8, 15 and 22.

Rituximabdrug

375 mg/m\^2 IV on Day 8 and 22.

Valacyclovirdrug

500 mg orally daily (or acyclovir 200 mg orally twice daily)